Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02201355 · ClinicalTrials.gov registry record · Phase 1
Hypofractionated Reduced-Volume Chemoradiation for T1/2N0-2 SCC Head and Neck
A Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02201355 is a Phase 1 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 8 participants.
The verdict
NCT02201355, a Phase 1 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Primary Objectives: To determine whether patients with T1/2N0-2 Squamous Cell Carcinoma of the oropharynx, hypopharynx or larynx can tolerate treatment with cisplatin chemoradiation in three weeks using reduced volume IMRT Secondary Objectives: To describe the adverse events associated with hypofractionated, reduced volume cisplatin chemoradiation. To estimate response rates and progression-free survival rates of hypofractionated, reduced volume cisplatin chemoradiation. To determine HRQOL following hypofractionated, reduced volume cisplatin chemoradiation. If patients can safely be treated in three weeks rather than six weeks, such a schedule would provide a much more convenient alternative for patients and result in a significant reduction in the health care resources currently expended on cure of these patients.
Interventions
- RADIATION Intensity Modulated Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-09-18 |
| Est. Completion | 2020-05-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02201355
The ClinicalTrials.gov registry entry for NCT02201355 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intensity Modulated Radiotherapy is the first listed.
NCT02201355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02201355 about?
NCT02201355 is a clinical study titled "Hypofractionated Reduced-Volume Chemoradiation for T1/2N0-2 SCC Head and Neck". Primary Objectives: To determine whether patients with T1/2N0-2 Squamous Cell Carcinoma of the oropharynx, hypopharynx or larynx can tolerate treatment with cisplatin chemoradiation in three weeks using reduced volume IMRT Secondary Objectives: To describe the adverse events associated with hypof...
What is the current status of trial NCT02201355?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2014-09-18. Estimated completion is 2020-05-15.
What interventions are being tested in trial NCT02201355?
The interventions under investigation include: Intensity Modulated Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT02201355?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.